The AAOA has partnered with DosedDaily to offer a free resource for residents to support the education and training of the next generation of Otolaryngologists. The General ENT DosedDaily program is available to residents for free and will now include…
Release Date: August 14, 2020; Expiration Date: August 13, 2021
Nasal polyps impact an estimated 13 million Americans. In particular, nasal polyps affect 45% of people with adult-onset asthma and approximately 30% of people with chronic rhinosinusitis, in the latter, it is known as chronic rhinosinusitis with nasal polyps (CRSwNP). The heterogeneity of CRSwNP may explain the recurrence of nasal polyps and the limitations of a “one size fits all” medical and surgical approach for the treatment for CRSwNP. The development of biologics targeting various aspects of chronic inflammation for the treatment of CRSwNP is evolving rapidly. This program discusses the prevalence and underlying pathophysiology of CRSwNP and the clinical trial data on emerging therapeutics options based on their mechanisms of action, efficacy, and safety data.
This initiative is intended for otolaryngologists (ENTs) interested in better understanding the role of biologics in reducing inflammation and related symptomatology in ENT disorders, especially nasal polyposis.
Upon completion of the educational activity, participants should be able to:
- Describe the prevalence and underlying pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP)
- Review the emerging biologic targets and treatment options for chronic rhinosinusitis with nasal polyps (CRSwNP)
- Evaluate the clinical trial data on emerging therapeutics options for chronic rhinosinusitis with nasal polyps (CRSwNP) based on their mechanisms of action, efficacy, and safety data
CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare
AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Criteria for Success
Statements of credit will be awarded based on the participant’s attendance, participation in the pre/post-test and submission of the activity evaluation form. A passing score of 70% on the quiz is required to receive credit. A certificate will be available upon successful completion of the quiz and evaluation. If you have questions about this CME activity, please contact AKH Inc. at email@example.com. There is no fee for this activity.
For more information and to participate in the activity please http://aaoacme.org/